Tumor reductive therapies and antitumor immunity

Area of Science:

• Oncology
• Immunology
• Cancer Therapeutics

Background:

• Traditional tumor reductive therapies (chemotherapy, radiation) primarily focus on direct tumor cell killing.
• The connection between tumor reductive therapies and antitumor immunity has been historically underexplored.
• Cancer immunotherapy, including cellular therapies and immune checkpoint inhibitors, has emerged as a distinct treatment category.

Purpose of the Study:

• To review the immunological perspective of classic cancer treatments.
• To explore the synergistic relationship between tumor reductive therapies and cancer immunotherapies.
• To argue that most cancer treatments ultimately exert efficacy through antitumor immunity.

Main Methods:

• Literature review of historical and recent findings.
• Analysis of clinical observations and animal studies.
• Examination of the impact of classic therapies on tumor antigens and antitumor immunity in vivo.

Main Results:

• The effectiveness of classic therapies is significantly influenced by the host's antitumor immune status.
• Immunotherapies demonstrate improved outcomes when combined with tumor reductive therapies due to synergistic effects.
• Classic therapies directly impact tumor antigens, influencing antitumor immunity more than previously recognized.

Conclusions:

• Most cancer treatments, including classic ones, exert their ultimate efficacy by modulating or leveraging antitumor immunity.
• Viewing classic therapies through an immunological lens explains their effectiveness and synergy with immunotherapy.
• Antitumor immunity plays a crucial role in tumor control and destruction, enhanced by various therapeutic modalities.